Cyclopropanesulfonamide → Cyclopropanesulfonic acid {17-[7-methoxy-8-methyl-2-(6-methyl-pyridin-2-yl)-quinazolin-4-yloxy]-13-methyl-2,14-dioxo-3,13,15-triazatricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl}-amide

HRID 1443474Notizen

Reaktionsgleichung

[CH3:1][O:2][C:3]1[C:12]([CH3:13])=[C:11]2[C:6]([C:7]([O:21][CH:22]3[CH2:39][CH:38]4[N:24]([C:25](=[O:45])[N:26]([CH3:44])[CH2:27][CH2:28][CH2:29][CH2:30][CH:31]=[CH:32][CH:33]5[C:35]([C:41](O)=[O:42])([NH:36][C:37]4=[O:40])[CH2:34]5)[CH2:23]3)=[N:8][C:9]([C:14]3[CH:19]=[CH:18][CH:17]=[C:16]([CH3:20])[N:15]=3)=[N:10]2)=[CH:5][CH:4]=1.[CH:46]1([S:49]([NH2:52])(=[O:51])=[O:50])[CH2:48][CH2:47]1>>[CH3:1][O:2][C:3]1[C:12]([CH3:13])=[C:11]2[C:6]([C:7]([O:21][CH:22]3[CH2:39][CH:38]4[N:24]([C:25](=[O:45])[N:26]([CH3:44])[CH2:27][CH2:28][CH2:29][CH2:30][CH:31]=[CH:32][CH:33]5[C:35]([C:41]([NH:52][S:49]([CH:46]6[CH2:48][CH2:47]6)(=[O:51])=[O:50])=[O:42])([NH:36][C:37]4=[O:40])[CH2:34]5)[CH2:23]3)=[N:8][C:9]([C:14]3[CH:19]=[CH:18][CH:17]=[C:16]([CH3:20])[N:15]=3)=[N:10]2)=[CH:5][CH:4]=1

Komponenten

Edukt 2

HCID 15765418Cyclopropanesulfonamide

HCID 6842448917-[7-Methoxy-8-methyl-2-(6-methyl-pyridin-2-yl)-quinazolin-4-yloxy]-13-methyl-2,14-dioxo-3,13,15-triaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid

Produkt 1

HCID 75290662Cyclopropanesulfonic acid {17-[7-methoxy-8-methyl-2-(6-methyl-pyridin-2-yl)-quinazolin-4-yloxy]-13-methyl-2,14-dioxo-3,13,15-triazatricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carbonyl}-amideAusbeute 22,6 %

Versuchsvorschrift

Compound 118 (50 mg, 0.08 mmol) was reacted with cyclopropanesulfonic acid amide (44 mg, 0.36 mmol) according to the procedure described in Example 53 which gave the title compound (13 mg, 22%). MS (M−H)+ 718.2

Quellen und Nachweise

ORD-Eintrag: ord-663fb556de6247279473b72d4e3bb84f
Quelldatensatz: uspto-grants-2010_02
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US07659245B2

Notizen zur Reaktion

Wird geladen…